High-risk multiple myeloma patients may benefit markedly from galinpepimut-S, an experimental immunotherapy from SELLAS Life Sciences, following autologous stem cell transplant (ASCT), according to recent data from a Phase 2 clinical trial showing that the agent nearly doubles the progression-free survival rates compared to historical controls who received ASCT alone.
Robots can do all sorts of tasks to improve cancer treatment and now researchers have added room cleaning to the list. Indeed, Robots that use ultraviolet light (UV) to clean hospital rooms reduce the rates of hospital-acquired infections among blood cancer patients, one of the most vulnerable groups of patients.
The U.S. Food and Drug Administration (FDA) is giving priority review to a supplemental Biologics License Application (sBLA) to approve Genmab‘s Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and Decadron (dexamethasone), or with Velcade (bortezomib) and Decadron, to treat multiple myeloma patients who have received at…
The communication between multiple myeloma cells and healthy bone marrow cells is an important step in disease progression, researchers have found, showing that multiple myeloma cells can cause changes in the nonmalignant bone marrow constituents that support the growth of malignant cells. The study, “Multiple myeloma cells…
The Multiple Myeloma Research Foundation (MMRF) is going to add its entire worth of genomic data to the Genomic Data Commons, a National Cancer Institute (NCI) database that aids precision care of myeloma by making cancer data publicly available. The addition of the multiple myeloma data to the repository…
Treatment of newly diagnosed multiple myeloma patients with a combination of Kyprolis (carfilzomib), Alkeran (melphalan), and prednisone does not yield superior outcomes, compared to the triple combination of Velcade (bortezomib), Alkeran, and prednisone, according to recent results of a Phase 3 trial. During the last decade, proteasome inhibition has emerged as an effective therapeutic strategy…
BioInvent International has received further patent protection in China, Japan, and Russia covering the use of BI-505 in cancer patients who have failed to respond to, or relapsed after, prior therapies. These patents add to those previously granted in these countries, as well as in Europe and the United States, covering…
Newly diagnosed multiple myeloma patients who are using statins have lower mortality rates than those who don’t, a large population-based cohort study reported. In the study, “Statins Are Associated With Reduced Mortality in Multiple Myeloma,” published in the Journal of Clinical Oncology, researchers at St.
PharmaMar has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the use of Aplidin (plitidepsin) in combination with Decadron (dexamethasone, an anti-inflammatory drug) for the treatment of relapsed/refractory multiple myeloma patients. The EMA’s decision is expected by the second half of 2017. The application was supported by…
The Multiple Myeloma Research Foundation (MMRF) and the Memorial Sloan Kettering Cancer Center are collaborating to launch a new clinical trial studying minimal residual disease (MRD) in multiple myeloma (MM) patients. The trial, titled “Carfilzomib, Lenalidomide, Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Translational MRD Study,” is expected to…
Get regular updates to your inbox.